Does TILDRAKIZUMAB Cause Off label use? 27 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 27 reports of Off label use have been filed in association with TILDRAKIZUMAB (ILUMYA). This represents 3.1% of all adverse event reports for TILDRAKIZUMAB.
27
Reports of Off label use with TILDRAKIZUMAB
3.1%
of all TILDRAKIZUMAB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Off label use From TILDRAKIZUMAB?
Of the 27 reports, 2 (7.4%) required hospitalization.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TILDRAKIZUMAB. However, 27 reports have been filed with the FAERS database.
What Other Side Effects Does TILDRAKIZUMAB Cause?
Product dose omission issue (53)
Death (50)
Drug ineffective (50)
Psoriasis (37)
Urinary tract infection (36)
Pneumonia (33)
Condition aggravated (25)
Covid-19 (25)
Inappropriate schedule of product administration (22)
Cerebrovascular accident (20)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which TILDRAKIZUMAB Alternatives Have Lower Off label use Risk?
TILDRAKIZUMAB vs TILDRAKIZUMAB-ASMN
TILDRAKIZUMAB vs TILIDINE
TILDRAKIZUMAB vs TIMOLOL
TILDRAKIZUMAB vs TIMOLOL\TRAVOPROST
TILDRAKIZUMAB vs TINIDAZOLE